Nominations close Thursday 27 January
Enter now

Investment in ADC Biotechnology

By Dan Teuton
3 November 2017
Share

Completion Date: 09/2017
Target: ADC Biotechnology
Deal Value: Undisclosed
Details: HMT LLP, led by partner Paul Read advised Maven
Capital Partners on its investment in anti-cancer drugs
manufacturer ADC Biotechnology
Funding: Maven Capital Partners
Financial Due Diligence: HMT

hmtllp.com

HMT-NEW-LOGO-August-2016-copie


Related topics

Related articles

Upcoming events

view more
02
Mar

Reading 2030

Royal Berkshire Conference Centre
9:00 am12:30 pm
More info
24
Mar

Solent Deals Awards 2022

Hilton Ageas Bowl
6:00 pm11:00 pm
More info
27
Apr

Southern Tech 150 Private Dinner & Awards

Oakley Hall Hotel, Basingstoke
6:00 pm10:00 pm
More info
26
May

Surrey Kent Sussex 250 private dinner

Denbies Wine Estate
6:00 pm10:00 pm
More info
08
Jun

South Coast Property Awards June 2022

Hilton at the Ageas Bowl, Southampton
6:00 pm11:00 pm
More info